Protagonist Therapeutics (NASDAQ: PTGX) — Perfil da empresa, notícias e dados financeiros
Protagonist Therapeutics focuses on innovative peptide-based drugs for gastrointestinal disorders and unmet medical needs.
Protagonist Therapeutics
Protagonist Therapeutics (NASDAQ:PTGX) is a biotechnology firm focused on discovering and developing innovative peptide-based drugs. Their operation spans the spectrum from early research to clinical development, with a particular emphasis on treating diseases by targeting the body's protein interactions. Their projects often revolve around gastrointestinal disorders, anemia, and other diseases where there is a significant unmet medical need. The objective of Protagonist Therapeutics is to leverage their proprietary technology platforms to create therapies that improve patient outcomes and potentially lead to better quality of life. The company is constantly exploring new avenues for their drug development process, aiming to expand their portfolio and impact on healthcare significantly.
Resumo
Operações
Produtos e/ou serviços de Protagonist Therapeutics
- Rusfertide (PTG-300) is an injectable hepcidin mimetic in development for polycythemia vera and other blood disorders.
- PN-943 is an oral, gut-restricted alpha-4-beta-7 integrin antagonist aimed at treating inflammatory bowel diseases.
- PTG-200 (JNJ-67864238) is an oral IL-23 receptor antagonist, co-developed with Janssen Biotech, targeting Crohn's disease and ulcerative colitis.
- PTG-100 is an oral peptide a4ß7 integrin antagonist being studied for potential treatment of ulcerative colitis.
- Rusfertide for hereditary hemochromatosis aims to reduce blood iron levels, offering a novel treatment option.
- Collaboration with Janssen Biotech focuses on the discovery and development of new integrin receptor antagonists for gastrointestinal diseases.
equipe executiva do Protagonist Therapeutics
- Dinesh V. PatelCEO, President, Secretary & Director
- Asif AliExecutive VP & CFO
- Arturo M. MolinaChief Medical Officer
- Venkat ThalladiEVP & Chief Technical Officer
- Newman YeildingExecutive VP, Chief Scientific Officer
- Matthew M. GoslingExecutive VP and Chief Legal & Business Officer
- Carena SpiveyExecutive VP & Chief Human Resources Officer
- Ashok BhandariEVP & Chief Discovery Officer
- Carter J. KingExecutive Vice President of Business Development
- Abha BommireddiExecutive VP & Chief of Staff
Principais indicadores financeiros
Resultados divulgados pela Protagonist Therapeutics, em USD.
- Cap. de mercado
- 9,2 bi
- Receita (TTM)
- 282 mi
- P/L
- 138.0
- LPA (diluído, TTM)
- 1.0
- Dividend yield
- —
- Margem de lucro
- 29.4%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 46 mi | -158,1 mi | -130,1 mi | |
| 434,4 mi | 252,8 mi | 275,2 mi | |
| 60 mi | -93,7 mi | -79 mi | |
| 26,6 mi | -131,4 mi | -123,4 mi |